Cart
sales@molnova.com
Bifenazate
CAS No. 149877-41-8
Bifenazate( —— )
Catalog No. M26629 CAS No. 149877-41-8
Bifenazate is a positive allosteric modulator of GABA receptor. Bifenazate is an acaricide that controls 100% of mites at a concentration of 25 ppm.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 26 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBifenazate
-
NoteResearch use only, not for human use.
-
Brief DescriptionBifenazate is a positive allosteric modulator of GABA receptor. Bifenazate is an acaricide that controls 100% of mites at a concentration of 25 ppm.
-
DescriptionBifenazate is a positive allosteric modulator of GABA receptor. Bifenazate is an acaricide that controls 100% of mites at a concentration of 25 ppm.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorGLUT2| SGLT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number149877-41-8
-
Formula Weight300.358
-
Molecular FormulaC17H20N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 250 mg/mL (832.36 mM)
-
SMILESCOc1ccc(cc1NNC(=O)OC(C)C)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Adachi T, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000 Aug;49(8):990-5.
molnova catalog
related products
-
Dimethocaine
Dimethocaine is a local anesthetic with reported stimulant properties most similar to cocaine.
-
Isosorbide
Isosorbide is a heterocyclic compound that is derived from glucose, used as a diuretic.
-
Allomatrine
Allomatrine is a natural product from Sophora alopecuroides L. Allomatrine when given i.c.v. may stimulate the descending dynorphinergic neuron resulting in the stimulation of KORs in the spinal cord.
